Ursula Schmidt-Erfurth, MD: Therapeutic Effect of Pegcetacoplan on GA Disease Activity
May 3rd 2023At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.
Andres Emanuelli, MD: Analysis of the Port Delivery System in the Phase 3 Pavilion Trial
May 3rd 2023At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.
Carl Danzig, MD: Analysis of GATHER Trials Connects GA Growth with Vision Loss
April 24th 2023In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.
Caroline Baumal, MD: Marking a New Treatment Era for GA with Pegcetacoplan
April 24th 2023At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.